Second dose of treatment generates response among young people during Oxford University trial
News
Incyte’s Opzelura gets MHRA authorisation
Therapy involves the treatment of non-segmental vitiligo among adults and adolescents
Novartis reveals five-year efficacy data for Kesimpta
Patients treated with Kesimpta experienced considerable decreases in relapse rates
GeneCode receives record Parkinson’s funding
European Innovation Council Accelerator finances treatment development drive for condition
Positive efficacy data for Sensorian’s candidate
SENS-401 has been developed for hearing preservation among adult patients following cochlear implantation
Vertex’s Orkambi receives EC approval
Orkambi is an oral treatment for very young children that combines both lumacaftor and ivacaftor
Teva reveals critical Ajovy data
Therapy has been developed to reduce the frequency, duration and severity of migraine attacks
King’s College London and Pioneer Group in incubator link-up
Collaboration aims to revitalise two empty sites on the South Bank of London by providing several laboratories
DigitalHealth.London’s Accelerator programme selects Aide
Project aims to boost the adoption of technology across London’s NHS and help patients manage conditions
BMS’ Sotyktu gets NICE green light for NHS use
The therapy becomes an option for moderate-to-severe plaque psoriasis in certain adults
Edinburgh researchers and LifeArc to boost MND treatment processes
Partnership will establish drug candidates using both laboratory tests and machine-learning
Genfit and Ipsen announce elafibranor results
ELATIVE, a randomised PBC trial involving 161 patients, has successfully met its primary endpoint
University of Oxford and PrecisionLife reach data agreement
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis
Momentum for Poolbeg and CytoReason’s AI collaboration
Partnership establishes several influenza therapy targets using artificial intelligence
TME Pharma reveals positive NOX-A12 data
GLORIA trial shows increased survival levels among newly diagnosed brain cancer patients
